Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(Telotristat etiprate; LX 1606 Hippurate; LX-1606 Hippurate)
LX1606 Hippurate Chemical Structure
|Product name: LX1606 Hippurate|
|Cat. No.: HY-13055|
LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
Target: Tryptophan hydroxylase
in vivo: LX1606 (LX 1606, LX-1606) is useful for Neurological Diseas . LX1606 were given orally to mice. LX1606 reduced 5-HT significantly in the gut and blood but not in the brain. oral LX1032 reduced the severity of TNBS-induced colitis; the expression of 24% of 84 genes encoding inflammation-related cytokines and chemokines was lowered at least fourfold and the reduced expression of 17% was statistically significant . Treatment with LX1606 showed a strong positive effect in ameliorating TNBS-induced IBD in mice as assessed by various parameters of disease development. These preclinical data demonstrate that inhibition of TPH activity by LX1606 may provide a new approach for the treatment of IBD and its serotonin-mediated symptoms.
|M.Wt||754.15||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: ≥ 28 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||1.3260 mL||6.6300 mL||13.2600 mL|
|5 mM||0.2652 mL||1.3260 mL||2.6520 mL|
|10 mM||0.1326 mL||0.6630 mL||1.3260 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|LX1606 Hippurate||Lexicon Pharmaceuticals Inc||31-AUG-13||Phase 1||24-OCT-13|
|Lexicon Pharmaceuticals Inc||Ulcerative colitis||31-DEC-11||31-AUG-13||Phase 2||24-OCT-13|
|Lexicon Pharmaceuticals Inc||Carcinoid syndrome||31-MAY-10||Phase 2||12-NOV-13|
|Lexicon Pharmaceuticals Inc||Carcinoid syndrome||31-OCT-12||30-APR-15||Phase 3||30-OCT-13|
|Lexicon Pharmaceuticals Inc||Carcinoid syndrome||31-MAR-09||31-DEC-13||Phase 2||11-NOV-13|
LX-1031 is an oral, small molecule tryptophan 5-hydroxylase (TPH) inhibitor that reduces serotonin (5-HT) synthesis peripherally.